

A New Total Synthesis of the Marine Tunicate Alkaloid Lepadiformine


Pu Sun, Cuixiang Sun, and Steven M. Weinreb*

Department of Chemistry, The Pennsylvania State University,
University Park, Pennsylvania 16802

smw@chem.psu.edu

Received August 16, 2001

ABSTRACT



A total synthesis of racemic lepadiformine has been achieved via a route that utilizes as key steps a novel stereocontrolled intramolecular spirocyclization of an allylsilane/*N*-acyliminium ion and the application of our radical-based methodology for production of *N*-acylimines from *o*-aminobenzamides.

During the past decade a number of structurally related tricyclic alkaloids have been isolated from various marine ascidians. The most common and numerous alkaloids of this type are the cylindricines, isolated from *Clavelina cylindrica* collected off the coast of Tasmania, whose structures were established by the Blackman group.¹ The cylindricines are comprised of two subclasses: the pyrrolo-quinolines represented by **1**–**4**, and the pyrido-quinolines typified by **6**. Interestingly, cylindricines A (**1**) and B (**6**) form a 3:2 equilibrium mixture presumably via interconversion through aziridinium intermediate **5**. In addition, several cylindricines exist within both classes that have a butyl group and/or differing stereochemistry at C2. In 1997 another alkaloid, fasicularin (**7**), was isolated from the ascidian *Neptheis fasicularis*.² Compound **7** is related structurally to the cylindricine B pyrido-quinoline alkaloids, but it is epimeric at the C10 quaternary center and in addition lacks the C4 oxygenation found in the cylindricines. Fasicularin is active against a DNA repair deficient strain of yeast and is also cytotoxic.

In 1994, Biard and co-workers reported the isolation of the alkaloid lepadiformine from the tunicate *Clavelina lepadiformis* Muller collected in the Mediterranean near Tunisia.³ The compound has also been found in *Clavelina moluccensis* collected near Djibouti. Primarily on the basis of NMR spectroscopic data, lepadiformine was formulated as having the pyrrolo-quinoline constitution **8** related to the cylindricine A series of alkaloids. The compound was also suggested to have the very unusual zwitterionic structure shown. Lepadiformine was found to have moderate in vitro cytotoxic activity against several tumor lines.³ In addition, various cardiovascular effects of lepadiformine in vivo and in vitro have been described.⁴

We recently reported the synthesis of the structure **8** proposed for lepadiformine and demonstrated that the compound does not exist as a zwitterion and that neither the free amine nor its hydrochloride salt correspond to the natural product.⁵ Simultaneously, Pearson et al. prepared the other three diastereomers of this structure at C2 and C13 and found

(1) (a) Blackman, A. J.; Li, C.; Hockless, D. C. R.; Skelton, B. W.; White, A. H. *Tetrahedron* **1993**, *49*, 8645. (b) Li, C.; Blackman, A. J. *Aust. J. Chem.* **1994**, *47*, 1355. (c) Li, C.; Blackman, A. J. *Aust. J. Chem.* **1995**, *48*, 955.


(2) Patil, A. D.; Freyer, A. J.; Reichwein, R.; Carte, B.; Killmer, L. B.; Faucette, L.; Johnson, R. K.; Faulkner, D. J. *Tetrahedron Lett.* **1997**, *38*, 363.

(3) Biard, J. F.; Guyot, S.; Roussakis, C.; Verbist, J. F.; Vercauteren, J.; Weber, J. F.; Boukef, K. *Tetrahedron Lett.* **1994**, *35*, 2691. The absolute configuration of lepadiformine is presently unknown.

(4) Juge, M.; Grimaud, N.; Biard, J. F.; Sauviat, M. P.; Nabil, M.; Verbist, J. F.; Petit, J. Y. *Toxicol.* **2001**, *39*, 1231.

(5) Werner, K. M.; De los Santos, J. M.; Weinreb, S. M.; Shang, M. J. *Org. Chem.* **1999**, *64*, 686. Werner, K. M.; De los Santos, J. M.; Weinreb, S. M.; Shang, M. J. *Org. Chem.* **1999**, *64*, 4865.

Scheme 1




that none of these isomers were lepadiformine.⁶ This structural problem was finally settled by Kibayashi and co-workers, who prepared compound **9** by total synthesis using an intramolecular Diels–Alder based approach and found that its hydrochloride salt is identical to natural lepadiformine.⁷ Moreover, it was determined by X-ray crystallography that the alkaloid exists with the ring bearing the hexyl group in the boat conformation indicated. Thus, lepadiformine is in the fascicularin (**7**) stereochemical series but with a pyrrolo-quinoline ring system.

Our synthetic approach to the original lepadiformine structure **8** was based upon a pivotal intramolecular nitronene-diene dipolar cycloaddition.^{5,8} However, this strategy cannot be modified to establish the requisite stereochemistry at the C10 quaternary center in **9**. Thus we have investigated a new approach to lepadiformine (**9**) based on a novel stereoselective intramolecular allylsilane/*N*-acyliminium ion spirocyclization⁹ followed by an application of our radical-based methodology for generation of *N*-acylimines as key steps.¹⁰ In this communication we report the results of this study.

The synthesis commenced with commercially available 2-methyl-1-pyrroline (**10**), which was first lithiated¹¹ and then alkylated with known iodide *Z*-allylsilane **11** (Scheme 1).¹² Without purification, the product of this reaction was *N*-acylated with *o*-nitrobenzoyl chloride to afford a mixture of regioisomeric enamides **12**, which was directly treated with trifluoroacetic acid to produce spirocycle **14** as a single stereoisomer (57% overall yield based upon **10**).¹³ The structure and conformation of this cyclization product were established by X-ray crystallography.¹⁴ We believe **14** forms via *N*-acyliminium ion conformation **13**. Conformer **15**, which would lead to the isomeric spirocycle **16**, is probably destabilized relative to **13** as a result of a steric interaction between the *N*-*o*-nitrobenzoyl group and the newly forming cyclohexane ring.

With spirocycle **14** in hand, we next turned to activation of the compound at C13 in order to introduce the requisite hydroxymethyl group of the natural product. Thus, the nitro functionality of **14** was cleanly reduced with NaBH₄/Cu-(acac)₂¹⁵ to provide *o*-aminobenzamide **17**, which was



(6) Pearson, W. H.; Barta, N. S.; Kampf, J. W. *Tetrahedron Lett.* **1997**, 38, 3369. Pearson, W. H.; Ren, Y. *J. Org. Chem.* **1999**, 64, 688.

(7) Abe, H.; Aoyagi, S.; Kibayashi, C. *J. Am. Chem. Soc.* **2000**, 122, 4583.

(8) For synthetic work on the cylindricines, see: Snider, B. B.; Liu, T. *J. Org. Chem.* **1997**, 62, 5630. Molander, G. A.; Ronn, M. *J. Org. Chem.* **1999**, 64, 5183. Liu, J. F.; Heathcock, C. H. *J. Org. Chem.* **1999**, 64, 8263.

(9) Reviews of the chemistry of *N*-acylimines: (a) Speckamp, W. N.; Hiemstra, H. *Tetrahedron* **1985**, 41, 4367. (b) Hiemstra, H.; Speckamp, W. N. In *The Alkaloids*; Brossi, A., Ed.; Academic Press: San Diego, 1988; Vol. 32, p 271. (c) Hiemstra, H.; Speckamp, W. N. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 2, p 1047. (d) Speckamp, W. N.; Moolenaar, M. *J. Tetrahedron* **2000**, 56, 3817.

(10) (a) Han, G.; McIntosh, M. C.; Weinreb, S. M. *Tetrahedron Lett.* **1994**, 35, 5813. (b) Han, G.; LaPorte, M. G.; McIntosh, M. C.; Weinreb, S. M.; Parvez, M. *J. Org. Chem.* **1996**, 61, 9483. (c) Chao, W.; Weinreb, S. M. *Tetrahedron Lett.* **2000**, 41, 9199.

(11) For C-alkylations of metalated endocyclic imines, see: (a) Gramain, J.-C.; Husson, H.-P.; Troin, Y. *J. Org. Chem.* **1985**, 50, 5517. (b) Evans, D. A. *J. Am. Chem. Soc.* **1970**, 92, 7593.


(12) Hiemstra, H.; Sno, M. H. A. M.; Vijn, R. J.; Speckamp, W. N. *J. Org. Chem.* **1985**, 50, 4014.

(13) For some related spirocyclizations leading to histrionicotoxins see, *inter alia*: Tanner, D.; Hagberg, L. *Tetrahedron* **1998**, 54, 7907. Evans, D. A.; Thomas, E. W.; Cherpeck, R. E. *J. Am. Chem. Soc.* **1982**, 104, 3695. David, M.; Dhimane, H.; Vanucci-Bacque, C.; Lhomme, G. *Heterocycles* **2001**, 55, 941.

(14) We are grateful to Dr. Louis Todaro (Hunter College, CUNY) for the X-ray analyses of compounds **14** and **20**.

subjected to the conditions we developed for conversion of such functionality to an α -methoxybenzamide (NaNO₂, HCl, MeOH, cat. CuCl), thereby producing **18** in good yield (Scheme 2).¹⁰ It was then possible to alkylate α -methoxy-

Scheme 2^a




^a Reagents: (a) NaBH₄, Cu(acac)₂, EtOH, rt, 95%; (b) NaNO₂, HCl, CuCl, MeOH, 0 °C–rt, 81%; (c) CH₂=CHCH₂Si(Me₂)CH₂MgBr, BF₃·Et₂O, CuBr₂·Me₂S, Et₂O, –78 °C–rt, 87%; (d) (i) BF₃·HOAc, CH₂Cl₂, rt; (ii) 35% H₂O₂, NaHCO₃, MeOH, THF, Δ , 95%.

benzamide **18** with the cuprate derived from (allyldimethylsilyl)methylmagnesium bromide¹⁶ to afford an 87% yield of a 7:1 mixture of diastereomeric products, with the desired silane **19** being the major isomer. This transformation presumably occurs via the preferred attack of the cuprate from the least hindered face of an intermediate *N*-acyliminium ion. A Tamao oxidation¹⁶ then served to convert silane **19** to the hydroxymethyl compound **20**, whose structure was confirmed by X-ray crystallography.¹⁴

Continuing the synthesis, terminal alkene **20** was hydroformylated¹⁷ to produce an aldehyde that was immediately converted to the corresponding dimethyl acetal **21** (Scheme 3). Hydrolytic cleavage of the benzoyl group of **21** with LiOH in aqueous ethanol then provided amino alcohol **22**. After some experimentation, it was eventually concluded that for introduction of the C2 hexyl chain (vide infra) it was necessary to protect the hydroxyl group of **22**.¹⁸ Therefore, amino alcohol **22** was converted to the benzyl ether **23**, and exposure of this compound to acid led to the unstable tricyclic enamine **24**. Without purification, this material was transformed to the somewhat more stable amino nitrile **25** using HCl/KCN. Compound **25** appears to be a single stereoisomer, which we have tentatively assigned as having the boat structure shown on the basis of ¹H NMR coupling constant data and by analogy with lepadiformine (**9**).¹⁹

It was then possible to introduce the hexyl chain by treating crude amino nitrile **25** with commercially available hexyl-


Scheme 3^a



^a Reagents: (a) Rh(CO)₂acac, CO/H₂ (1:1), THF, P(OPh)₃, 60 °C; (b) MeOH, HCl, (MeO)₃CH, rt, 81% from **20**; (c) 15% LiOH, Δ , EtOH, H₂O, 99%; (d) BnBr, NaH, THF, –8 °C–rt, 75%; (e) *p*-TsOH, Me₂CO, H₂O, Δ ; (f) HCl, MeOH, KCN, Me₂CO, H₂O, rt.

magnesium bromide in the presence of boron trifluoride etherate to produce a 3:1 mixture of the desired alkylation product **28** along with its C2 epimer **29** (56% overall yield from amino acetal **23**) (Scheme 4).²⁰ The results of this

Scheme 4^a



^a Reagents: (a) C₆H₁₃MgBr, BF₃·Et₂O, THF, –20 °C–rt, 67% from **23**; (b) Na, NH₃, THF, –78 °C.

reaction can be rationalized on the basis of the stereoelectronic principles delineated by Stevens.²¹ Thus, anti-periplanar addition of the Grignard reagent to intermediate iminium

(19) However, we cannot distinguish between the structure shown in **24** and the epimeric one in which the cyano group is equatorial in a chair conformation.

(15) Hanaya, K.; Muramatsu, T.; Kudo, H.; Chow, Y. L. *J. Chem. Soc., Perkin Trans. 1* **1979**, 2409.

(16) Tamao, K.; Ishida, N. *Tetrahedron Lett.* **1984**, 25, 4249.

(17) Ojima, I.; Tsai, C.-Y.; Tzamarioudaki, M.; Bonafoux, D. *Org. React.* **2000**, 56, 1.

(18) The unprotected hydroxymethyl analogue of amino nitrile **24** could be prepared, but this compound could not be alkylated successfully with hexyl Grignard reagents or cuprates.

salt **26** from a preferred “axial” direction would lead to an initial chair **27**, which ring flips to the more stable lepadiformine boat conformation **28**. Attack on iminium species **26** from the opposite (“equatorial”) direction initially produces an unfavorable boat, which converts to the more stable chair/equatorial hexyl conformer **29**.

Cleavage of the benzyl ether group from the C2 epimers **28** and **29** using sodium/ammonia afforded racemic lepadiformine (**9**) and the epimeric alcohol **30**, respectively, in high yields. Synthetic alkaloid **9** and its HCl salt have spectral data identical to those of authentic material.²² Thus, we have prepared lepadiformine in approximately 15 steps and 11% overall yield starting from readily available 2-methyl-1-pyrroline (**10**).

Acknowledgment. We are grateful to the National Institutes of Health (CA-34303) for financial support of this research.

Supporting Information Available: Experimental procedures for the preparation of new compounds, including spectral data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL010179Y

(20) Polniaszek, R. P.; Belmont, S. E. *J. Org. Chem.* **1990**, *55*, 4688.

(21) Stevens, R. V. *Acc. Chem. Res.* **1984**, *17*, 289.

(22) We thank Professor J. F. Biard for copies of the proton and carbon NMR spectra, as well as a sample of natural lepadiformine. We are also grateful to Professor Ray Funk for NMR spectra of synthetic lepadiformine free base (**9**) and the corresponding hydrochloride; see: Funk, R. L.; Greshock, T. L. *Org. Lett.* **2001**, *3*, 3511.